Why Has BCMA Become the Core Target in Multiple Myeloma Treatment? What New Target Opportunities Exist Beyond BCMA?
In the evolving landscape of Multiple Myeloma treatment, targeted therapies have shifted from a supportive role to a central pillar.
Among them, BCMA (B-cell maturation antigen) has rapidly transitioned from a promising target to a therapeutic cornerstone within just a few years, fundamentally reshaping the treatment paradigm for relapsed/refractory multiple myeloma (RRMM).
At the same time, challenges related to resistance and relapse are driving the field to accelerate exploration of novel targets beyond BCMA.
As a global pharmaceutical distribution platform focused on improving access to innovative therapies, DengYueMed closely monitors the implementation of cutting-edge treatments across markets, particularly breakthroughs in hematologic malignancies.
This article explores why BCMA has become central in multiple myeloma treatment and examines emerging target opportunities beyond BCMA from both mechanistic and industry perspectives.
Why BCMA: From an Ideal Target to a Therapeutic Core
BCMA has rapidly established itself as a core target due to its unique combination of specificity and functional relevance.
It is primarily expressed on mature B cells and plasma cells, with significantly elevated expression on myeloma cells, while showing minimal presence in other normal tissues.
This expression pattern allows for precise tumor targeting with a relatively favorable safety profile.
Importantly, BCMA is not merely a surface marker—it plays a direct role in tumor cell survival and proliferation.
Through interaction with its ligands APRIL and BAFF, BCMA activates downstream signaling pathways such as NF-κB, thereby sustaining tumor growth at a mechanistic level.
From a target quality perspective, BCMA offers several key advantages:
● Highly restricted expression in tumor-related cells, enabling a clearer therapeutic window
● Direct involvement in critical survival pathways rather than redundant signaling routes
● Stable membrane expression, facilitating recognition by antibodies and cell-based therapies
These characteristics make BCMA one of the few targets capable of supporting multiple therapeutic modalities.
Three Major Therapeutic Modalities Built Around BCMA
The true value of BCMA lies not only in its targetability, but in the diverse therapeutic strategies built upon it:
1. CAR-T: A Benchmark for Deep Responses
BCMA-directed CAR-T therapies have demonstrated remarkably high response rates in RRMM, with some patients achieving minimal residual disease (MRD) negativity and prolonged progression-free survival.
These therapies involve engineering a patient’s own T cells to achieve precise and sustained tumor killing.
However, limitations remain, including complex individualized manufacturing, long production timelines, and high costs, which restrict broader accessibility.
2. Bispecific Antibodies: Off-the-Shelf Immunotherapy
Represented by Teclistamab, BCMA/CD3 bispecific antibodies simultaneously engage T cells and myeloma cells, enabling direct immune-mediated tumor killing.
These agents are readily available without the need for individualized production and support repeat dosing, significantly improving clinical accessibility.
Nevertheless, long-term use may be associated with infection risk and immunosuppression.
3. ADCs: Precision-Delivered Cytotoxic Therapy
Belantamab Mafodotin represents another important BCMA-targeted strategy, delivering cytotoxic payloads directly to tumor cells via antibody conjugation for targeted cell killing.
Compared to cell therapies, ADCs offer more convenient administration and do not rely on complex immune cell manipulation.
Recently, Belantamab Mafodotin was approved in China. For a deeper understanding of its mechanism of action and key clinical evidence, please refer to our feature article:Belantamab Mafodotin Approved in China for Multiple Myeloma: First-in-Class BCMA ADC Marks New Milestone
The Limitations of BCMA: Challenges Behind Success
With the widespread use of BCMA-targeted therapies, their limitations are becoming increasingly apparent. The more extensively they are used, the more concentrated these challenges become.
Key issues include:
● Antigen escape: Reduced or lost BCMA expression at relapse in some patients
● Target competition: Sequential use of different BCMA therapies may impact efficacy
● Complex resistance mechanisms: Involving both tumor-intrinsic and immune-related factors
● Toxicity concerns: Including CAR-T-related cytokine release syndrome (CRS) and ADC-related adverse events
These challenges highlight that BCMA, while powerful, is unlikely to serve as a standalone solution.
Beyond BCMA: Emerging Targets Forming a Second Wave
As BCMA-based therapies mature, the field is actively advancing toward a “post-BCMA” target landscape. Several emerging targets are forming a second tier, with complementary mechanisms and applications:
1. GPRC5D: The Most Promising “Next BCMA” Candidate
GPRC5D is highly expressed in myeloma cells, with limited expression in normal tissues (primarily skin and hair follicles), making it an attractive target.
Clinically, GPRC5D/CD3 bispecific antibodies such as talquetamab have demonstrated efficacy even in patients previously treated with BCMA-targeted therapies, suggesting minimal cross-resistance.
However, skin-related toxicities and taste disturbances require attention.
2. FcRH5: A Target with Stable Expression
FcRH5 is consistently expressed throughout the B-cell lineage and is less prone to antigen loss, which is particularly valuable for long-term treatment strategies.
Agents such as cevostamab are currently being evaluated for their potential across multiple lines of therapy.
Compared to BCMA, FcRH5 offers greater expression stability and may serve as an important alternative in resistant settings.
3. CD38: From Established Target to Combination Backbone
Although not a novel target, CD38 is being redefined in the current treatment landscape.
Represented by daratumumab, CD38-targeted therapies have evolved from monotherapy to key components in combination regimens. In combination with CAR-T or bispecific antibodies, CD38 is increasingly positioned as an immunomodulatory backbone.
4. Additional Targets: Expanding Therapeutic Boundaries
Other targets such as SLAMF7 and CD19 continue to play roles in specific patient populations or combination strategies.
For example, SLAMF7 may provide synergistic effects in immunomodulatory regimens, while CD19 could target earlier or progenitor-like tumor populations.
Although these targets may not become dominant, they hold meaningful value in personalized treatment approaches.
Future Trends: From Single-Target Competition to Multi-Target Synergy
Multiple myeloma treatment is transitioning from a single-target paradigm to a multi-target, system-level strategy. This shift is already reflected in evolving clinical approaches:
● Sequential therapy: BCMA → GPRC5D → FcRH5
● Combination therapy: Bispecifics with other bispecifics, or with CAR-T and small molecules
● Multispecific antibodies: Simultaneously targeting multiple antigens
The overarching goals are:
● To reduce antigen escape
● To delay resistance
● To improve long-term survival outcomes
Conclusion
BCMA has become the core target in multiple myeloma treatment not only because of its ideal biological characteristics, but also because it has successfully enabled a multi-modality therapeutic ecosystem.
However, as clinical experience deepens, its limitations are becoming clearer.
The future does not lie in replacing BCMA, but in building a dynamic, multi-target therapeutic network around it. From GPRC5D and FcRH5 to multispecific antibody strategies, multiple myeloma is entering a new era of precision-driven, long-term disease management.
In this evolving landscape, DengYueMed will continue to track global advancements in innovative therapies and improve access to cutting-edge treatments, bridging the gap between innovation and clinical needs for patients and the healthcare ecosystem.
- Like
- Reply
-
Share
About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2026 MolecularCloud